BioSpace News Archive

Protagenic Therapeutics, Inc. announced a step forward in its mission to address stress-related neuro-psychiatric disorders.

NeuroMetrix, Inc. announced a process to review strategic options to promote growth of its Quell® neuromodulation and DPNCheck® neurodiagnostic businesses and to maximize shareholder value.

A proprietary cognitive assessment from Linus Health, a digital health company focused on enabling early detection of Alzheimer’s and other dementias, outperforms the most commonly used paper-based assessment in detecting early mild cognitive impairment and dementia and with less ethnic and racial bias, according to a peer-reviewed study recently published in the prestigious medical journal Alzheimer’s Research & Therapy.

Sunshine Biopharma, Inc. today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $10.0 million, before deducting underwriting fees and other estimated offering expenses payable by the Company.

American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRD) (“Aires” or the “Company”), a company focused on scientifically-proven EMF modulation technology, announces that, due to higher than anticipated investor demand

Adial Pharmaceuticals, Inc. today announced it has been awarded an important patent which expands the estate covering the combination of the Company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder.

Innsena today announced its partnership with CancerX , a public-private partnership announced by The White House as a national accelerator to boost digital innovation in the fight against cancer.

BIOLASE, Inc. today announced the pricing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock.

Intrinsic Therapeutics, Inc. announced the appointment of Dave Amerson and Tyler Binney to its Board of Directors.

OsteoCentric Technologies, inventor of UnifiMI, an implant-to-bone interface technology, capable of sustaining primary implant stability, is thrilled to announce that Jason E. Topolosky, MBA, MTM/MSE will be joining the company as Chief Business Officer.